Charg­ing for ex­pand­ed ac­cess drugs: FDA to let com­pa­nies re­coup their costs over time

The FDA on Mon­day up­dat­ed guid­ance from 2016 on how com­pa­nies can charge for in­ves­ti­ga­tion­al drugs un­der an IND, now telling spon­sors work­ing un­der ex­pand­ed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER